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Abstract
Background:  Recovery of iodide uptake in thyroid cancer cells by means of obtaining the
functional expression of the sodium/iodide symporter (NIS) represents an innovative strategy for
the treatment of poorly differentiated thyroid cancer. However, the NIS gene expression alone is
not always sufficient to restore radioiodine concentration ability in these tumour cells.
Methods: In this study, the anaplastic thyroid carcinoma ARO cells were stably transfected with
a Pax8 gene expression vector. A quantitative RT-PCR was performed to assess the thyroid specific
gene expression in selected clones. The presence of NIS protein was detected by Western blot
and localized by immunofluorescence. A iodide uptake assay was also performed to verify the
functional effect of NIS induction and differentiation switch.
Results: The clones overexpressing Pax8 showed the re-activation of several thyroid specific
genes including NIS, Pendrin, Thyroglobulin, TPO and TTF1. In ARO-Pax8 clones NIS protein was
also localized both in cell cytoplasm and membrane. Thus, the ability to uptake the radioiodine was
partially restored, associated to a high rate of efflux. In addition, ARO cells expressing Pax8
presented a lower rate of cell growth.
Conclusion: These finding demonstrate that induction of Pax8 expression may determine a re-
differentiation of thyroid cancer cells, including a partial recovery of iodide uptake, fundamental
requisite for a radioiodine-based therapeutic approach for thyroid tumours.
Background
Thyroid tumours show a good long-term survival, but,
when we consider the poorly differentiated histotypes and
in particular the anaplastic carcinoma, the prognosis is
very poor [1,2]. A major determinant of such an opposite
behaviour is the lost ability to concentrate the
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radioiodine, used as very effective tool for diagnosis and
treatment for both tumour remnants or distant metastases
[3]. The loss of iodide uptake capacity in poorly differen-
tiated thyroid carcinomas is mainly due to the reduced/
lost functional expression of the sodium/iodide sym-
porter (NIS), with a defect occurring mainly at gene
expression level, but in some case involving post-tran-
scriptional or other unknown alterations [4-7]. For this
reason, many strategies have been used and are currently
in progress in order to re-establish iodide uptake function
by means of re-expressing the NIS in tumour cells. At
present, two different strategies are based on: a. introduc-
ing NIS gene in cancer cells through a viral vector; b. stim-
ulating endogenous NIS gene expression [5,7]. The latter
approach may take advantage from the description and
characterization of the human NIS gene promoter as well
as studies regarding NIS expression regulation [4-7].
Among the physiological stimulators of NIS gene tran-
scription, a pivotal role is played by the thyroid-specific
transcription factor Pax8 [8-10]. This homeobox protein
is able to regulate, in normal thyroid cells, the expression
of many thyroid specific protein and is often reduced in
thyroid tumours, especially in the less differentiated histo-
types [11].
In this study we analysed the effects of Pax8 overexpres-
sion on a human thyroid anaplastic cancer cell line ARO
cells. It is a widely used cell line which resembles the
behaviour of poorly differentiated thyroid tumours,
including a very low iodide uptake function as well as lost
of NIS and Pax8 gene expression, together with several
other markers of thyrocyte differentiation [12]. By restor-
ing Pax8 expression, we observed the recovery of NIS
expression, together with other markers of thyroid differ-
entiation, associated to partial ability to uptake the
radioiodine.
Methods
Recombinant plasmid construction
The plasmid vector pCMV and the full length cDNA frag-
ment of Pax8 A (kindly provided by Dr. Di Lauro) [13],
were cleaved by Kpn I and Eco RI. The cleaved products
were ligated using T4DNA ligase into pCMV-Script clon-
ing and expression vector (Stratagene, La Jolla, CA, USA).
DH5 alpha cells were transformed using the recombinant
product pCMV/Pax8 and then screened for the positive
clones containing the inserted fragment by colony-PCR
techniques. The positive colonies were amplified,
extracted, purified and identified by endonuclease cleav-
age. The sequences of the inserted fragments were con-
firmed by automated sequencing using ABI Prism 7700
Sequence Detector (Applied Biosystems, Foster City, CA,
USA).
Cell cultures and stable transfection
ARO cells were cultured in RPMI 1640 medium with 10%
foetal bovine serum (Gibco, Milano, Italy) and containing
penicillin/streptomycin and amphotericin B (Sigma-
Aldrich S.r.l., Milano, Italy). The non-liposomal lipid mix-
ture FUGENE 6 (Roche diagnostics, Monza, Italy) was
used for transfection. ARO cells were plated at 3 × 105
cells/60 mm culture dish 24 h prior to transfection. 2 mg
of the construct and 2 µg of empty vector in 200 µl of
serum free medium and 12 µl of FUGENE 6 mixture each,
were used for two different transfections. After 45 min of
incubation at room temperature, the transfection mixture
was added to the dishes with 2 ml of fresh complete
medium. The cells were grown for 24 h before adding 400
µg/ml neomycin (Sigma-Aldrich S.r.l.) for selection and
after 3 days the transfected cultures were split for single
clone isolation. After propagation, total RNA was
extracted from 24 isolated clones for screening of Pax8
gene expression by a quantitative RT-PCR. Cells trans-
fected with the empty vector (ARO-pCMV) were used as
control. FRTL-5 and CHO cells, used as additional con-
trol, were cultured as described previously [14].
RNA extraction, reverse transcription and quantitative 
PCR
Total RNA was extracted from cells with using the Qiagen
RNA/DNA kit (Qiagen S.p.A, Milano, Italy), according to
manufacturer's instructions. First-strand cDNA synthesis
was performed using 2 µg of each RNA sample primed
with random hexamers with 200 U of Superscript II
reverse transcriptase (Life Technologies S.r.l., San
Giuliano milanese, Milano, Italy). Quantitative PCR anal-
ysis (Q-PCR) of Pax8, NIS, Thyroperoxidase (TPO), TSH-
Receptor (TSH-R), Thyroid transcription factor-1 (TTF1)
and pendrin (PDS) mRNA expression was performed on
cDNA samples employing the primers indicated in Table
1. Oligonucleotide primers and probe were purchased
from Applied Biosystems as Assays-on-Demand Gene
Expression Products for the study of Thyroglobulin (Tg),
endogenous control glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) and β -actin were purchased from
Applied Biosystems as TaqMan PDAR (VIC dye-labeled).
A 25 µl reaction mixture containing 2.5 µl of cDNA tem-
plate, 12.5 µl TaqMan Universal PCR master mix (Applied
Biosystems) and 1.25 µl primer probe mixture was ampli-
fied using the following thermal cycler parameters: incu-
bation at 50°C for 2 min and denaturing at 95°C for 10
min, then 40 cycles of the amplification step (denatura-
tion at 95°C for 15 sec and annealing/extension at 60°C
for 1 min). For each amplification run standard curve was
generated using 6 serial dilutions of cDNA mix expressing
all the genes analysed. All amplification reactions were
performed in triplicate, and the averages of the threshold
cycles were used to interpolate standard curves and to cal-
culate the transcript amount in samples using SDS versionBMC Cancer 2005, 5:80 http://www.biomedcentral.com/1471-2407/5/80
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1.7a software. Levels of mRNA expression were expressed
after normalization with those of two endogenous con-
trols, GAPDH and β -actin.
Protein extraction, western blot analysis and 
immunofluorescence
Total proteins were extracted from thyroid cell lines as
described previously [15]. Briefly, confluent cells from 3
Petri dishes were collected and homogenized in 1 ml of
buffer containing 250 mM sucrose, 10 mM HEPES-KOH
(pH 7.5), 1 mM EDTA, 1 mM PMSF, 10 µg/ml leupeptin,
10 µg/ml aprotinin (Sigma-Aldrich S.r.l.). The homoge-
nate was centrifuged at 14000 × g (4°C for 15 min) and
the supernatant (which contained the whole cell lysate)
was quantified spectrophotometrically using the Bradford
method. Twenty micrograms of proteins were loaded on a
4–20% gradient SDS-polyacrylamide gel and subjected to
electrophoresis at a constant voltage (110 V). Electroblot-
ting to a Hybond ECL-PVDF nitrocellulose membrane
(Amersham Pharmacia biotech., Milano, Italy) was per-
formed for 2 h at 125 mA using a Mini Trans blot electrob-
lotting system (Bio-rad Laboratories S.r.l, Milano, Italy).
Blocking was done using TTBS/milk (TBS, 1% Tween 20,
and 5% non fat dry milk) for 2 h at room temperature.
The membrane was then incubated with a 1/500 dilution
of affinity purified rabbit anti-NIS polyclonal antibody
[16] or a 1/5000 dilution of mouse monoclonal anti-
human beta-actin antibody, overnight at 4°C in TTBS/
milk. After one 15 min and two 5 min washes in TTBS, the
membrane was incubated with a 1/20000 dilution of a
horse radish peroxidase conjugated anti-rabbit or anti-
mouse antibody (Transduction Laboratories, Lexington,
KY, USA) in TTBS/milk. After one 15 min and two 5 min
washes in TTBS, the protein was visualized by an
enhanced chemiluminescence Western blot detection sys-
tem (ECL plus, Amersham Pharmacia biotech.).
For immunofluorescence analysis, the cells were plated on
glass coverslips and fixed using PBS containing 4% para-
formaldehyde for 10 min at RT. Then the fixative was aspi-
rated and the cells washed 3 times for 5 min each with
PBS. The cells were incubated with blocking buffer (PBS
1× + BSA 1%) for 15 min at RT. Immunostaining was per-
formed using 1:600 dilution of a rabbit polyclonal anti-
body anti h-NIS [15] for 1 h at RT. After three 5-min
washes in PBS, the cells were incubated with secondary
antibody conjugate with FITC (Sigma Aldrich S.r.l.)
diluted 1:160 in PBS 1×, for 30 min at RT, re-washed in
PBS and incubated in Hoechst 1× for 3 min at RT. After
three final PBS washes, the cells were mounted with
Vectashield (Vector Laboratories, Inc. Burlingame, CA,
USA).
Iodide uptake, efflux rate and cell growth rate assay
Uptake of 125I was measured as previously described [17].
Briefly, cells were splitted and seeded into 12-well plates
and, after aspirating the culture medium, washed with 1
ml of Hank's balanced salt solution (HBSS) (Life technol-
ogies S.r.l) supplemented with Hepes 10 mM, pH 7.3. 125I
uptake was initiated by adding to each well 500 µl buff-
ered HBSS containing 0.1 µCi carrier-free Na125I and 10
µM NaI to obtain a specific activity of 20 mCi/mmol.
In half of the wells, this assay buffer was supplemented
with the NIS inhibitor KClO4 (10 µM) to control for spe-
cific uptake. After 40 min at 37°C in a humid atmosphere,
the radioactive medium was aspirated and cells were
washed with 1 ml of ice-cold HBSS. One ml of 95% etha-
nol was added to each well for 20 min and then trans-
ferred into vials for counting with a gamma counter.
Iodide uptake was expressed as picomoles per µg of DNA.
Each experiment was done at least twice in quadruplicates
and the FRTL-5 cells and CHO cells were used, respec-
tively, as positive and negative controls.
Iodide efflux in wild-type and transfected ARO cells, as
well FRTL-5 cells, was evaluated as previously described
by Arturi et al. [14].
For cell growth rate analysis, 105 cells were plated in 60
mm dishes. Seven hours were considered as extra time
needed from cells to sediment and start to proliferate.
Table 1: Sequences of primer pairs and TaqMan probes
Gene Primer forward Primer reverse Probe
Pax8 5'-CAACAGCACCCTGGACGAC-3' 5'-AGGGTGAGTGAGGATCTGCC-3' 5'-CTGACCCCTTCCAACACGCCACTG-3'
NIS 5'-CCATCCTGGATGACAACTTGG-3' 5'-AAAAACAGACGATCCTCATTGGT-3' 5'-AGAACTCCCCACTGGAAACAAGAAGCCC-3'
TPO 5'-ACGCCTCTGCGAGGTGC-3' 5'-TGCAAATCACCGTCGAGGT-3' 5'-TGCTGATCGGAGGCTTCGCAG-3'
TSH-R 5'-CCTTCACCTCACACGGGCT-3' 5'-TGCTCTCATTACACATCAAGGACTC-3' 5'-TTTCTTACCCAAGCCACTGCTGTGCC-3'
TTF-1 5'-CCTGTCCCACCTGAACTCCTC-3' 5'-GCCTTTGTGGTTTTTTGTTCC-3' 5'-CGGACTACGGCACCATGTCCTGC-3'
Pendrin 5'-CATCAAGACATATCTCAGTTGGACCT-3' 5'-ACAGTTCCATTGCTGCTGGAT-3' 5'-TCTGAGCATGGCCCCCGACG-3'
For Thyroglobulin gene were used primers and probes provided by Applied Biosystems (Assays-on-demand gene products).BMC Cancer 2005, 5:80 http://www.biomedcentral.com/1471-2407/5/80
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Cells were harvested after 24, 48 and 72 hours and the
number of cells was determined by Neubauer cell count-
ing chamber.
Results
ARO cells were transfected with the pCMV-Script-hPax8
construct or the expression vector alone. A series of 24
clones were grown and screened for the presence of the
insert (data not shown). Pax8 mRNA levels were quanti-
fied by real time RT-PCR method and ARO-Pax8 clones 8
and 21 were selected in that they overexpressed different
amounts of Pax8 transcript (Fig. 1).
Since Pax8 has a key role in thyroid differentiation, we
first checked in the ARO-Pax8 cells the presence of a series
of thyroid specific genes. Fig. 2 shows the levels of the
transcripts detected in the two clones versus wild-type
ARO cells or ARO transfected with the empty vector
(ARO-pCMV). The highest mRNA expression levels were
detected for Thyroglobulin gene (more than 20 fold in
ARO-PAX8 clone 21), but also NIS, Pendrin, TPO and
TTF1 gene were expressed in PAX8 clones with different
levels of the transcripts depending on the different
amount of Pax8 transcript (Fig. 2). All the transcript
expression levels resulted lower (ranging between 10 and
100 fold) than those detectable in normal thyroid tissue
(data not shown). The mRNA of the TSH receptor did not
appear in the transfected cell clones (data not shown).
Goal of the study, however, was to verify the possibility to
recover the ability to concentrate the radioiodine. For this
reason we evaluated the NIS protein levels by Western
blot analysis and its localization by immunofluorescence,
together with the ability of ARO-Pax8 cells to uptake the
radioiodine. As shown in Fig. 3, NIS protein was detected
in both clones and its amount paralleled that of the corre-
sponding transcripts of NIS and Pax8. However, only few
amount of the protein reached the plasmamembrane, as
detected by immunofluorescence (Fig. 4). Accordingly, a
low, but significant rate of radioiodine uptake reappeared
in ARO-Pax8 cells with a similar pattern between the two
Levels of expression of Pax8 mRNA in the wild-type and  transfected ARO cells Figure 1
Levels of expression of Pax8 mRNA in the wild-type and 
transfected ARO cells. ARO cells were transfected with a 
pCMV expression vector empty or containing the hPax8 
gene, as described in Methods. Total RNA was extracted 
from duplicate dishes of wild-type ARO cells (ARO), cells 
containing the empty vector (ARO-pCMV) and two selected 
clones expressing Pax8 gene (ARO-Pax8 cl. 8 and ARO-Pax8 
cl. 21 (as described in Methods) and the levels of RNA were 
determined using the real-time PCR method. To normalize 
the different amount of total RNA added to the reaction, an 
amplification of GAPDH or β -actin was performed as endog-
enous control. The data are expressed as the mean ± SD of 
values obtained from at least three different experiments. 
Statistic analysis was performed using the one-factor 
ANOVA, followed by t test. P < 0.05 was considered statisti-
cally significant.
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Levels of mRNA of various thyroid specific genes in wild-type  and transfected ARO cells Figure 2
Levels of mRNA of various thyroid specific genes in wild-type 
and transfected ARO cells. Total RNA was extracted from 
duplicate dishes of wild-type ARO cells (ARO), cells contain-
ing the empty vector (ARO-pCMV), two selected clones 
expressing Pax8 gene (ARO-Pax8 cl. 8 and ARO-Pax8 cl. 21) 
and the levels of RNA were determined using the real-time 
PCR method. To normalize the different amount of total 
RNA added to the reaction, an amplification of GAPDH or 
β -actin was performed as endogenous control. The data are 
expressed as the mean ± SD of values obtained from at least 
three different experiments. Statistic analysis was performed 
using the one-factor ANOVA, followed by t test. P < 0.05 
was considered statistically significant.
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clones and at much lesser extent than normal thyrocytes
(Table 2). It was inhibited by perchlorate (10 µM) (Table
2) and not stimulated by activation of the cAMP pathway
obtained by incubating the cells with 10 µM of Forskolin
(data not shown). A high rate of efflux was also observed,
at similar extent in both clones expressing Pax8 and earlier
and much higher than that detected in FRTL-5 cells (Fig.
5).
Finally, in the ARO-Pax8 clones, we observed a lower
growth rate in comparison to ARO non transfected cells
(Fig. 6).
Discussion
A modified gene expression represents the basis for the
development and acquisition of the abnormal growth and
differentiation characteristics of tumour cells. Since the
regulation of the gene expression takes place mainly at
transcriptional level, structural or functional alterations of
transcription factors, especially those specific for a given
tissue, play a key role in the oncogenic process [18]. In
thyroid cells, the simultaneous expression of a cohort of
tissue-specific transcription factors, including TTF1, TTF2,
Pax8 and HEX has been described [19]. Their expression
and correct function is essential for the normal
development of thyroid gland, and is often altered
(reduced or lost) in thyroid tumours, especially in the
poorly differentiated histotypes [11]. As a result, thyroid
tumour cells present a dedifferentiated phenotype,
including a reduced/lost ability to concentrate the radio-
iodine. This feature represents one of the major determi-
nant of the poor prognosis of less differentiated thyroid
carcinomas, since it does not allow the use of radioiodine
as diagnostic and therapeutic tool for both tumour rem-
nants or distant metastases. For this reason, attempts to
reintroduce such a functional activity in tumour cells have
represented the goal of many studies. The cloning and
characterization of the protein responsible for iodide
uptake, the NIS [20], has opened the way to novel thera-
peutic strategies based on induction of iodide uptake abil-
ity in tumour cells by recovery the expression of the NIS
gene. Subsequently, a NIS-based gene therapy approach
by using viral vectors has been exploited [4-7]: despite
promising results obtained in both in vitro and in vivo
experimental models, unresolved issues still remain
before proposing such a treatment on humans, mainly a
great efflux rate of the administered radioiodine which
makes the effective dose of radioisotope (to be adminis-
tered to destroy the tumour tissue) too high to be side
effect free. A parallel approach to restore radioiodine
uptake is to induce endogenous NIS expression and cor-
rect function by acting on its transcriptional regulation.
Various molecules have been challenged, including retin-
oids, demethylating agents and inhibitors of histone
deacetylation [21-25], with preliminary promising effects
in various in vitro and in vivo experimental models. How-
ever, in poorly differentiated thyroid tumour cells, re-
expression of NIS protein is not always accompanied by
recovery of its function [26] and, at present, despite their
unequivocal activity in vitro, retinoids did not show a suf-
ficient effectiveness in clinical trials on human patients
[27]. Probably, alterations of other proteins, including
some involved in the intrathyroidal metabolism of iodine
or in the correct folding, trafficking, polar localization and
function of the NIS, do occur in tumour cells, making not
fully effective the simple restoration of NIS expression.
In this work, we explored an alternative way to recover
radioiodine concentration ability in thyroid tumour cells.
Indeed, we tried to activate the transcriptional machinery
which physiologically control NIS gene expression by act-
ing on its promoter, as well as other thyroid specific gene
Expression of NIS protein in ARO cells expressing different  levels of Pax8 gene Figure 3
Expression of NIS protein in ARO cells expressing different 
levels of Pax8 gene. Western Blot analysis was performed as 
described in Methods. In upper panel/autoradiograph of a 
representative experiment. In lower panel/the staining inten-
sity is expressed as mean ± SD of values obtained from three 
different experiments. The data are expressed relative to the 
control values (cells transfected with the empty vector, 
ARO-pCMV). Statistic analysis was performed using the one-
factor ANOVA, followed by t test. P < 0.05 was considered 
statistically significant.
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cooperating to express the differentiated thyrocyte pheno-
type. On this regard, the paired domain-containing pro-
tein Pax8 has been characterized for its physiological role
in the development of thyroid tissue and maintenance of
thyrocyte differentiation phenotype [28,29]. Moreover,
reduction/lost of Pax8 expression has been described in
thyroid tumour tissues and cell lines [[11], our unpub-
lished observations]. Pax8-binding sites have been
described in the promoters of human TPO, Thyroglobulin
and recently, also NIS gene [8,9]. In addition, re-expres-
sion of Pax8 was associated with the recovery of the NIS,
as well as TPO and Tg mRNA expression in a rat thyroid
cell line [30]. An effect on Tg and TPO promoter activity
had been previously described, in cooperation with TTF-
1, also in human thyroid tumour cell lines [31].
Our study demonstrates that thyroid tumour cells express-
ing Pax8 after stable transfection become able to uptake
the radioiodine, even if in absence of a full recovery of NIS
protein expression on their plasmamembrane. In
addition, other markers of thyroid differentiation were
detectable after Pax8 expression, including proteins
involved in the intrathyroidal metabolism of iodine such
as TPO and pendrin. The expression levels of these thy-
roid-specific genes were strictly related to the amount of
Pax8 expressed in the transfected clones, emphasizing the
importance of the levels of this transcription factor for
Immunofluorescent localization of NIS in ARO cells Figure 4
Immunofluorescent localization of NIS in ARO cells. ARO-pCMV and ARO-Pax8 cl. 21 cells were analyzed by immunofluores-
cence microscopy using rabbit polyclonal anti-NIS and anti-rabbit FITC secondary antibody. A: NIS (green) localization; B. Dou-
ble immunofluorescence with blue that indicates DAPI nuclear staining and green that indicates the NIS localization. 
Magnification: 40×.
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A
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determining a differentiated phenotype [32]. It is of inter-
est also our finding of the recovery of TTF-1 gene expres-
sion in the cells with higher levels of Pax8 which suggests
a regulatory role for Pax8 at TTF-1 gene promoter level. It
may contribute to the phenotypical effects observed and
confirms the existence of various levels of cooperation
among tissue specific transcription factors [33]. On this
regard, few data are available about TTF1 gene promoter,
although previous experimental data had suggested the
TTF1 gene as a candidate target for regulation by home-
obox proteins [34].
However, Pax8 and TTF1 do not determine a full recovery
of normal thyrocyte phenotype, as demonstrated by the
presence of lower expression levels of the transcripts in
comparison with normal thyroid tissue and the absence of
detectable levels of the TSH receptor even in the clones
overexpressing Pax8, and, more important, the low intra-
cellular retention of radioiodide. In ARO cells, a greater
efflux rate had been also observed after overexpression of
exogenous NIS gene inserted in a viral vector [35]; simi-
larly, only a faint iodide uptake reappeared in BHP18-21v
thyroid tumour cells expressing TTF1 [36]. Moreover, con-
trasting results have been reported after stimulation of
Iodide efflux studies in wild-type and transfected ARO cells Figure 5
Iodide efflux studies in wild-type and transfected ARO cells. Wild-type and transfected ARO cells (black circles) and FRTL-5 
(red squares) grown to 95% confluency in 35-mm diameter plates were incubated in shaking water bath for 60 min at 37°C in 
HBSS buffer containing 10 µM NaI and 1 µC 125I. To evaluate the iodide efflux, the medium was removed and replaced with 1 
ml of non-radioactive medium every 2 min. After removal of the last medium (20 min) cells were extracted using 1 ml ethanol 
(see Methods). The values shown are the counts per min remaining (as percentage of the total) at the indicated times. The 
experiment has been performed two fold, being no differences in the obtained data.
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Table 2: Radioiodide uptake in wild-type and transfected ARO cells
Cell type Iodide uptake (cpm/well)
P + KClO4 P
ARO wild-type 133 ± 35 78 ± 26 **0.09
ARO pCMV 137 ± 42 *0.9 82 ± 47 **0.2
ARO-PAX8 clone 8 307 ± 43 *0.006 126 ± 27 **0.003
ARO-PAX8 clone 21 257 ± 36 *0.01 104 ± 26 **0.004
FRTL-5 4350 ± 320
CHO 40 ± 12
Iodide uptake was analyzed as described in Methods. The FRTL-5 cells and CHO cells were used as positive and negative controls, respectively. 
Iodide uptake was expressed as the mean ± SD of values obtained from three separate experiments. Statistic analysis was performed using the one-
factor ANOVA, followed by t test. P < 0.05 was considered statistically significant.
* ARO PAX8 clone 8, clone 21 and ARO pCMV vs ARO wild-type;
** Uptake with vs Uptake without KClO4
Growth rate of wild-type and transfected ARO cells Figure 6
Growth rate of wild-type and transfected ARO cells. 105 cells were plated in 60 mm dishes. Seven hours were considered as 
extra time needed from cells to sediment and start to proliferate. Cells were harvested after 24, 48 and 72 hours and the 
number of cells was determined by Neubauer cell counting chamber. *p value <0.001
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endogenous NIS expression by inhibition of histone
deacetylation: by using valproic acid, Fortunati et al. [26]
did not obtain a correct localization of the NIS protein in
the thyrocyte plasmamembrane, whereas Furuya et al.
[25] described a full recovery of iodide uptake also in ARO
cells using the histone deacetylase inhibitor depsipeptide.
In addition, our observation of the slower growth rate of
ARO-Pax8 cells suggest a role for Pax8 in the control of
such a function, until now never detected. Altogether,
these data indicate that in addition to act on NIS transcrip-
tion, a more complex strategy including the correct target-
ing to the plasmamembrane is required to reach the goal
of an effective radioiodine intracellular concentration.
Conclusion
Our finding demonstrate that overexpression of thyroid-
specific transcription factors may be a first step to obtain
the radioiodine concentration by the transformed thyro-
cytes, by acting on a pool of differentiation markers
including the NIS. Our data, therefore, represent a very
promising starting point for further investigations and
strategies exploiting this effect of Pax8, eventually in com-
bination of other thyroid-specific transcription factors, for
extending radioiodine treatment also to the less differen-
tiated thyroid tumours.
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